ACCG-2671
Sources
registry, as of 2026-09-14Stale
https://clinicaltrials.gov/study/NCT07815678
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. Enrollment 164. Conditions Obesity. This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll
ClinicalTrials.gov NCT07815678 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07815678
and Part 3 will enroll otherwise healthy participants with obesity. ACCG-2671 is a nonpeptide dual amylin and calcitonin receptor agonist (DACRA) This study comprises 3 parts: Part 1 (Single Ascending Dose \[SAD\]) will be conducted in healthy participants to assess the safety, tolerability, and PK profile of a sing
NCT07815678 description or intervention text